Abstract
OBJECTIVE: To compare the clinical efficacy and safety of anticoagulation combined with catheter-directed urokinase (UK) thrombolysis vs. anticoagulation combined with catheter-directed alteplase (rt-PA) infusion thrombolysis in patients with intermediate-risk acute pulmonary embolism (APE). METHODS: A retrospective analysis was conducted on intermediate-risk APE patients treated at our center between June 2022 and May 2025, all of whom received anticoagulation combined with catheter-directed thrombolysis. The UK group (n = 56) received continuous UK infusion via pulmonary artery catheter (400,000-500,000 IU/day for 2-3 days), while the rt-PA group (n = 23) received intraprocedural rt-PA infusion (20 mg/30 min). Changes in cardiac troponin I (cTnI), N-terminal pro-brain natriuretic peptide (NT-proBNP), right ventricular diameter/left ventricular diameter (RVD/LVD), and pulmonary artery obstruction index (PAOI) were compared before and after treatment. RESULTS: Baseline characteristics showed no significant differences between groups (P > 0.05). Post-treatment, the UK group demonstrated significant improvements in PAOI, RVD/LVD, NT-proBNP, and cTnI (P < 0.05), while the rt-PA group showed significant improvements in PAOI, RVD/LVD, and cTnI (P < 0.05) but not NT-proBNP (P = 0.088). There were no statistically significant differences in the aforementioned indicators between the two groups at both pre-treatment and post-treatment time points (P > 0.05). There were no statistically significant differences in in-hospital mortality, the incidence of bleeding adverse events, and hospital stay duration between the two groups (P > 0.05). CONCLUSION: For intermediate-risk APE, catheter-directed UK thrombolysis and intraprocedural rt-PA infusion offer comparable efficacy and safety. However, the rt-PA regimen may be more advantageous due to its avoidance of prolonged catheter placement.